Skip to main content

Table 5 Effects of tofogliflozin on markers of renal function, inflammation, and cardio-vascular function

From: Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

  Tofogliflozin group Conventional group P value
eGFR (mL/min/1.73 m2) 80.7 ± 20.8 (n = 168) 81.9 ± 24.0 (n = 169) 0.64
 Week 26 (change from baseline) − 2.9 ± 9.1 (n = 161)§ − 2.8 ± 9.4 (n = 162)§ 0.89
 Week 52 (change from baseline) − 2.8 ± 9.5 (n = 159)§ − 2.3 ± 9.6 (n = 161)# 0.67
 Week 78 (change from baseline) − 3.2 ± 9.9 (n = 154)§ − 3.7 ± 10.4 (n = 157)§ 0.65
 Week 104 (change from baseline) − 3.1 ± 12.1 (n = 155)# − 3.8 ± 10.5 (n = 153)§ 0.59
UAE at baseline (mg/g/cre) 13.0 [6.3, 37.0] (n = 158) 17.4 [5.8, 67.7] (n = 157) 0.24
 Week 26 (change from baseline) − 0.3 [− 8.9, 6.7] (n = 139) − 0.4 [− 9.5, 4.5] (n = 134) 0.83
 Week 52 (change from baseline) − 1.7 [− 8.1, 3.9] (n = 146)* 0.1 [− 5.7, 9.6] (n = 146) 0.038
 Week 78 (change from baseline) − 0.8 [− 8.3, 8.0] (n = 131) 1.1 [− 6.4, 13.9] (n = 130) 0.06
 Week 104 (change from baseline) − 1.4 [− 9.9, 5.4] (n = 144) 1.8 [− 3.9, 20.1] (n = 140)* 0.006
hsCRP at baseline (ng/ml) 582.5 [287.5, 1430.0] (n = 168) 619.5 [295.0, 1450.0] (n = 170) 0.70
 Week 52 (change from baseline) − 24.5 [− 298.0, 190.0] (n = 154) 0.0 [− 260.0, 311.0] (n = 159) 0.41
 Week 104 (change from baseline) − 45.0 [− 412.5, 172.5] (n = 152) 18.5 [− 300.5, 305.0] (n = 152) 0.21
Adiponectin at baseline (μg/ml) 7.50 [5.30, 10.30] (n = 168) 7.35 [5.40, 10.30] (n = 170) 0.88
 Week 52 (change from baseline) 0.65 [0.10, 1.30] (n = 154)§ 0.40 [− 0.30, 1.10] (n = 159)§ 0.019
 Week 104 (change from baseline) 0.70 [− 0.10, 1.80] (n = 152)§ 0.25 [− 0.30, 1.00] (n = 152)# 0.003
NT-proBNP at baseline (pg/ml) 34.0 [17.0, 68.0] (n = 168) 31.5 [17.0, 59.0] (n = 170) 0.96
 Week 52 (change from baseline) − 1.0 [− 14.0, 11.0] (n = 154) − 2.0 [− 13.0, 9.0] (n = 159) 0.94
 Week 104 (change from baseline) 1.0 [− 12.0, 17.0] (n = 152) 2.0 [− 8.5, 17.0] (n = 152)* 0.50
  1. Data are presented as mean ± SD or median (the 25th and 75th percentiles) values. Differences in parameters between groups at baseline were analyzed using Student’s t-test or Wilcoxon rank-sum test. Differences in parameters from baseline to week 52 and 104 within each group were analyzed between groups using a one-sample t-test or Wilcoxon signed-rank test. Differences in parameter changes from baseline to week 52 and 104 were analyzed using Student’s t-test or Wilcoxon rank-sum test. *P < 0.05, #P < 0.01, §P < 0.001
  2. eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro–brain natriuretic peptide; baPWV, brachial-ankle pulse wave velocity; ABI, ankle brachial blood pressure index